You are a key healthcare player, who develops and/or markets medicines, vaccines, medical devices or in-vitro diagnostics.
You are looking for a provider able to optimise the value of your products to health authorities and other decision makers, in order to maximize their reimbursement level.
stève consultants is a consulting specialist in Market Access and HEOR studies. Our qualified consultants, our network and our human approach focusing on deliverables quality and timelines compliance makes our company a key player in France since 2006.
years of experience
consultants
loyal customers
Stève Bénard – Executive Director
Josselin Boussel, Head of Market access
of stève consultants since 2010
Market access
For more than 10 years, stève consultants has been specialized in:
- strategic consulting for pricing & reimbursement,
- developing arguments and estimating target populations,
- writing of reimbursement dossiers for French health authorities (transparency, CNEDiMTS and economic dossiers).
Our bonus: Working closely with you through evaluations by the French National Authority for Health (HAS) as well as through pricing negotiations with the French Economic Committee of Healthcare Products (CEPS).
Health-economic modeling
Our dedicated consultants conceive and develop:
-
health economic evaluations for health authorities (efficiency evaluation for the French Economic Committee of Evaluations in Public Health (CEESP), pricing negotiations with the CEPS…)
-
simulation tools to serve the medico-marketing strategy
Design /
Adaptation
cost-effectiveness model
cost-utility model
budget impact model
Data
collection
epidemiology and clinical inputs
healthcare consumption
unit costs
Results
main analysis
uncertainty analysis
technical report
Our bonus: Strategic and technical guidance alongside the project.
Fanny Porte, HEOR Consultant
Charlotte Cancalon, Health-economist statistician
of stève consultants since 2009
Observational database studies
stève consultants realises your observational studies from databases, notably claims ones (PMSI, EGB, SNIIRAM):
-
post-inscription studies required by health authorities,
-
ad-hoc pharmaco-epidemiological, epidemiological or health-economic studies to sustain your Market access strategy
pharmaco
epidemiological
studies
proper
use studies
health-economic
studies
real life
efficiency
studies
Our bonus: Support of a dedicated scientific steering committee / possible cross with clinical registries or physicians’ panels.
